Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Acute promyelocytic leukemia (APL) is a well-defined malignancy characterized by a specific chromosomal translocation.
• Advances in understanding and targeted therapies have improved APL survival rates to over 80%.

Approach:

• Minimal residual disease (MRD) assessment is the cornerstone of APL management.
• Promyelocytic leukemia retinoic acid receptor α (PML-RARα) transcript detection via real-time quantitative PCR (RQ-PCR) is essential for monitoring MRD.
• RQ-PCR replaced qualitative PCR, offering precise numerical quantification of MRD.

Key Points:

• MRD assessment, particularly PML-RARα transcript detection, is critical for early relapse identification and guides preemptive treatment.
• Arsenic trioxide (ATO) therapy, alone or with all-trans-retinoic acid, expands the validation of MRD assessment.
• MRD monitoring shows efficacy in relapsed APL patients, including those undergoing stem cell transplantation or treated with other agents.

Conclusions:

• This review discusses the current state of MRD assessment in APL.
• MRD evaluation is vital for optimizing treatment strategies and improving outcomes in APL patients.